* Meets goal in proof-of-concept mid-stage trial
* Shares up 7 percent
May 14 (Reuters) - Medarex Inc MEDX.O said its rheumatoid arthritis (RA) drug, MDX-1100, met the main goal of a mid-stage proof-of-concept trial.
The main goal of the study was to show a 20 percent improvement in RA signs and symptoms at 12 weeks and the results were statistically significant when compared to a dummy drug, the company said.
The trial studied 70 patients who were receiving RA drug methotrexate. Patients were given either placebo or MDX-1100 every two weeks for a total of six doses.
Medarex said it plans to explore the potential of MDX-1100 in a range of inflammatory diseases.
Medarex shares were up 7 percent before the bell at $6.61. They closed at $6.17 Wednesday on Nasdaq. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Himani Sarkar)